Breaking News

Aslan Pharma and Selexis Team Up

Selexis to develop a proprietary cell line for expression of ASLAN004

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis SA, a life sciences company focused on mammalian cell line generation, and Aslan Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumor types, have entered into a service agreement under which Selexis will develop a CHO-K1 cell line for expression of ASLAN004, a novel fully human monoclonal antibody. ASLAN004 targets IL-13R-alpha1, and ASLAN is currently exploring its potential in a range of allergic disorders and onc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters